摘要
Abstract
Objective To explore the clinical value of quetiapine combined with lithium carbonate in the treatment of acute manic episodes in patients with bipolar disorder.Methods A retrospective analysis was conducted on the clinical data of 90 patients with acute manic episodes of bipolar disorder who visited Zunyi Yi-towanli Psychiatric Hospital from January 2023 to December 2024.Based on the order of admission,the patients were divided into a study group(45 cases)and a control group(45 cases).The manic symptoms,cognitive function,social functioning,inflammatory markers interleukin-1(IL-1),interleukin-6(IL-6),tumor necrosis factor-al-pha(TNF-α),oxidative stress markers superoxide dismutase(SOD),malondialdehyde(MDA),and clinical effi-cacy were compared between the two groups.Results Before treatment,there were no significant differences between the two groups in manic symptoms(BRMS scores),cognitive function(MoCA scores),social function(SSPI scores across 4 dimensions),inflammatory markers(IL-1,IL-6,TNF-α),and oxidative stress markers(SOD,MDA)(P＞0.05).After 8 weeks of treatment,both groups showed significant reductions in BRMS scores,IL-1,IL-6,TNF-α,and MDA(P＜0.001),and significant increases in MoCA scores,SSPI scores,and SOD levels(P＜0.05).Moreover,the changes in these indicators were significantly greater in the study group compared to the control group(P＜0.001).The total clinical efficacy rate in the study group was 97.78％,significantly higher than the 84.44％in the control group(P＜0.05).Conclusion In patients with acute manic episodes of bipolar disorder,the treatment regimen of quetiapine combined with lithium carbonate can effectively control manic symptoms,improve cognitive and social functions,and reduce the level of inflammatory stress response.关键词
喹硫平/碳酸锂/双相心境障碍Key words
Quetiapine/Lithium carbonate/Bipolar disorder分类
医药卫生
